Ligustrazine attenuates the platelet‑derived growth factor-BB-induced proliferation and migration of vascular smooth muscle cells by interrupting extracellular signal-regulated kinase and P38 mitogen-activated protein kinase pathways

Yu,Lifei; Huang,Xiaojing; Huang,Kai; Gui,Chun; Huang,Qiaojuan; Wei,Bin

doi:10.3892/mmr.2015.3383

Ligustrazine attenuates the platelet‑derived growth factor-BB-induced proliferation and migration of vascular smooth muscle cells by interrupting extracellular signal-regulated kinase and P38 mitogen-activated protein kinase pathways

Authors:
- Lifei Yu
- Xiaojing Huang
- Kai Huang
- Chun Gui
- Qiaojuan Huang
- Bin Wei
View Affiliations

Affiliations: Department of Cardiology, Western Hospital, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: February 24, 2015 https://doi.org/10.3892/mmr.2015.3383
Pages: 705-711

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) leads to intimal thickening of the aorta and is, therefore, important in the development of arteriosclerosis. As a result, the use of antiproliferative and antimigratory agents for VSMCs offers promise for the treatment of vascular disorders. Although several studies have demonstrated that ligustrazine may be used to treat heart and blood vessel diseases, the detailed mechanism underlying its actions remain to be elucidated. In the present study, the inhibitory effect of ligustrazine on platelet‑derived growth factor (PDGF)‑BB‑stimulated VSMC proliferation and migration, and the underlying mechanisms were investigated. The findings demonstrated that ligustrazine significantly inhibited PDGF‑BB‑stimulated VSMC proliferation. VSMCs dedifferentiated into a proliferative phenotype under PDGF‑BB stimulation, which was effectively reversed by the administration of ligustrazine. In addition, ligustrazine also downregulated the production of nitric oxide and cyclic guanine monophosphate, induced by PDGF‑BB. Additionally, ligustrazine significantly inhibited PDGF‑BB‑stimulated VSMC migration. Mechanistic investigation indicated that the upregulation of cell cycle‑associated proteins and the activation of the extracellular signal‑regulated kinase (ERK) and P38 mitogen‑activated protein kinase (MAPK) signaling induced by PDGF‑BB was suppressed by the administration of ligustrazine. In conclusion, the present study, demonstrated for the first time, to the best of our knowledge, that ligustrazine downregulated PDGF‑BB‑induced VSMC proliferation and migration partly, at least, through inhibiting the activation of the ERK and P38 MAPK signaling.

View Figures

View References

1	Gan J, Li P, Wang Z, et al: Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway. Exp Ther Med. 6:899–903. 2013.PubMed/NCBI
2	Lacolley P, Regnault V, Nicoletti A, Li Z and Michel JB: The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res. 95:194–204. 2012. View Article : Google Scholar : PubMed/NCBI
3	Shi N and Chen SY: Mechanisms simultaneously regulate smooth muscle proliferation and differentiation. J Biomed Res. 28:40–46. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zheng SD and Wu HJ: Progress of studies on effects of ligustrazine on blood vessel endothelium protection. Zhongguo Zhong Xi Yi Jie He Za Zhi. 31:1004–1008. 2011.In Chinese. PubMed/NCBI
5	Wang P, Luo CH, Wang QX, Li QY, Li P and Yuan XH: Antithrombotic effect of ligustrazine hydrochloride injection on the model of induced arteriovenous shunt thrombosis. J Res Med Sci. 18:704–706. 2013.
6	Luo ZL, Tian FZ, Tang LJ, et al: Protective effect of ligustrazine preconditioning on hepatic energy metabolism in ischemia/reperfusion injury of rat. Sichuan Da Xue Xue Bao Yi Xue Ban. 43:540–542. 2012.In Chinese.
7	Yu Y, Wang SR and Sun YK: Effects of ligustrazine on the mitochondrial structure and functions in the process myocardial hypertrophy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 32:661–665. 2012.In Chinese. PubMed/NCBI
8	Rocchiccioli S, Ucciferri N, Comelli L, Trivella MG, Citti L and Cecchettini A: Proteomics changes in adhesion molecules: a driving force for vascular smooth muscle cell phenotypic switch. Mol Biosyst. 8:1052–1059. 2012. View Article : Google Scholar : PubMed/NCBI
9	Orr AW, Hastings NE, Blackman BR and Wamhoff BR: Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res. 47:168–180. 2010. View Article : Google Scholar :
10	Liu G, Li X, Li Y, et al: PPARdelta agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling. Biomed Res Int. 2013:9039472013. View Article : Google Scholar
11	Park ES, Lee KP, Jung SH, et al: Compound K, an intestinal metabolite of ginsenosides, inhibits PDGF-BB-induced VSMC proliferation and migration through G1 arrest and attenuates neointimal hyperplasia after arterial injury. Atherosclerosis. 228:53–60. 2013. View Article : Google Scholar : PubMed/NCBI
12	Conti V, Russomanno G, Corbi G, Izzo V, Vecchione C and Filippelli A: Adrenoreceptors and nitric oxide in the cardiovascular system. Front Physiol. 4:3212013. View Article : Google Scholar : PubMed/NCBI
13	Gibiino S1, Marsano A and Serretti A: Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials. Int J Neuropsychopharmacol. 17:1–8. 2014. View Article : Google Scholar
14	Lim S and Kaldis P: Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
15	Sroka IM, Heiss EH, Havlicek L, et al: A novel roscovitine derivative potently induces G1-phase arrest in platelet-derived growth factor-BB-activated vascular smooth muscle cells. Mol Pharmacol. 77:255–261. 2010. View Article : Google Scholar
16	Pi Y, Zhang LL, Li BH, et al: Inhibition of reactive oxygen species generation attenuates TLR4-mediated proinflammatory and proliferative phenotype of vascular smooth muscle cells. Lab Invest. 93:880–887. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zhang XL, Liu LF, Zhu LY, et al: A high performance liquid chromatography fingerprinting and ultra high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry chemical profiling approach to rapidly find characteristic chemical markers for quality evaluation of dispensing granules, a case study on Chuanxiong Rhizoma. J Pharm Biomed Anal. 88:391–400. 2014. View Article : Google Scholar
18	Fan Z, Li C, Qin C, et al: Role of the PI3K/AKT pathway in modulating cytoskeleton rearrangements and phenotype switching in rat pulmonary arterial vascular smooth muscle cells. DNA Cell Biol. 33:12–19. 2014. View Article : Google Scholar
19	Karki R, Kim SB and Kim DW: Magnolol inhibits migration of vascular smooth muscle cells via cytoskeletal remodeling pathway to attenuate neointima formation. Exp Cell Res. 319:3238–3250. 2013. View Article : Google Scholar : PubMed/NCBI
20	Kobsar A, Klinker E, Kuhn S, et al: Increasing susceptibility of nitric oxide-mediated inhibitory platelet signaling during storage of apheresis-derived platelet concentrates. Transfusion. 54:1782–1789. 2014. View Article : Google Scholar : PubMed/NCBI
21	Qian J and Fulton D: Post-translational regulation of endothelial nitric oxide synthase in vascular endothelium. Front Physiol. 4:3472013. View Article : Google Scholar :
22	Yoon J and Ryoo S: Arginase inhibition reduces interleukin-1beta-stimulated vascular smooth muscle cell proliferation by increasing nitric oxide synthase-dependent nitric oxide production. Biochem Biophys Res Commun. 435:428–433. 2013. View Article : Google Scholar : PubMed/NCBI
23	Ataya B, Tzeng E and Zuckerbraun BS: Nitrite-generated nitric oxide to protect against intimal hyperplasia formation. Trends Cardiovasc Med. 21:157–162. 2011. View Article : Google Scholar
24	Yao M, Roberts DD and Isenberg JS: Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP. Pharmacol Res. 63:13–22. 2011. View Article : Google Scholar :
25	Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
26	Muslin AJ: MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond). 115:203–218. 2008. View Article : Google Scholar